CoChat

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis

Open access
Liu, Song, Hu, Jiaqiang, Zhao, Chen, Liu, Hang, He, Chunyang · 2025 · Frontiers in Endocrinology

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background The rapid development of multi-receptor drugs targeting glucagon-like peptide-1 receptor (GLP-1R) is driving significant advancements in the treatment of individuals with type 2 diabetes and obesity. This systematic review and network meta-analysis aims to compare the efficacy and safety of multi-receptor drugs in adults with overweight or obesity, with or without type 2 diabetes. Methods A systematic search was conducted in PubMed, Cochrane, Web of Science, Embase, CNKI, and WanFang databases up to May 12, 2024. Randomized controlled trials (RCTs) with an intervention duration of at least 12 weeks were included. The population of interest consisted of individuals with overweight or obesity, with or without type 2 diabetes. Eligible studies compared multi-receptor drugs with placebo or other multi-receptor drugs. The primary outcomes were weight reduction, glycated hemoglobin (HbA 1c ), fasting plasma glucose (FPG), blood pressure changes, and adverse events. Risk of bias was assessed using the version 2 of the Cochrane risk-of-bias tool (ROB2), and a random-effects network meta-analysis was performed using the frequentist approach. Confidence in effect estimates was evaluated using the Confidence In Network Meta-Analysis (CINeMA) framework. Results A total of 24 trials, involving 9165 participants, were included. Retatrutide (mean difference (MD): -11.91 kg, 95% CI: -19.00 to -4.82, P-score: 0.80, p: 0.0003) and Tirzepatide (MD: -12.78 kg, 95% CI: -16.10 to -9.46, P-score: 0.89, p < 0.0001) exhibited superior efficacy in reducing body weight, with all other agents except Mazdutide (MD: -5.31 kg, 95% CI: -9.78 to -0.84, P-score: 0.37, p: 0.0189) achieving reductions of over 8 kg. In patients with type 2 diabetes, all agents reduced HbA 1c by over 1%, with Tirzepatide (MD: -1.87%, 95% CI: -2.15 to -1.59, P-score: 0.87, p < 0.0001) and Mazdutide (MD: -1.89%, 95% CI: -2.43 to -1.35, P-score: 0.88, p < 0.0001) showing the greatest effects on glycemic control. For blood pressure management, Tirzepatide significantly reduced systolic blood pressure (MD: -6.69 mmHg, 95% CI: -7.62 to -5.75, P-score: 0.84, p < 0.0001) and diastolic blood pressure (MD: -3.73 mmHg, 95% CI: -4.75 to -2.71, P-score: 0.92, p < 0.0001), with nearly all agents lowering systolic blood pressure by more than 5 mmHg. Non-diabetic participants showed more pronounced improvements in both weight and blood pressure. Safety analysis revealed that Tirzepatide had a favorable safety profile and all agents showed no significant impact on serious adverse events compared to placebo. Conclusions Multi-receptor drugs demonstrated substantial therapeutic potential in weight management, glycemic control, and blood pressure regulation in adults with overweight or obesity, with or without diabetes, with a generally favorable safety profile. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024554005.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2025.1513641

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram of the study selection process.
Figure 1 PRISMA flow diagram of the study selection process.CC BY · PubMed Central
Figure 2 The network diagrams of all eligible comparisons for the primary outcomes of efficacy and safety. (A) Body weight (kg); (B) The proportion of participants achieving a weight loss of more than 5% (%); (C) HbA1c (%); (D) FPG (mmol/L); (E) Systolic blood pressure (mmHg); (F) Diastolic blood pressure (mmHg); (G) Adverse effect; (H) Serious adverse effect.
Figure 2 The network diagrams of all eligible comparisons for the primary outcomes of efficacy and safety. (A) Body weight (kg); (B) The proportion of participants achieving a weight loss of more than 5% (%); (C) HbA1c (%); (D) FPG (mmol/L); (E) Systolic blood pressure (mmHg); (F) Diastolic blood pressure (mmHg); (G) Adverse effect; (H) Serious adverse effect.CC BY · PubMed Central
Figure 3 Network meta-analysis results for the primary outcomes of efficacy and safety. (A) Body weight (kg); (B) The proportion of participants achieving a weight loss of more than 5% (%); (C) HbA1c (%); (D) FPG (mmol/L); (E) Systolic blood pressure (mmHg); (F) Diastolic blood pressure (mmHg); (G) Adverse effect; (H) Serious adverse effect.
Figure 3 Network meta-analysis results for the primary outcomes of efficacy and safety. (A) Body weight (kg); (B) The proportion of participants achieving a weight loss of more than 5% (%); (C) HbA1c (%); (D) FPG (mmol/L); (E) Systolic blood pressure (mmHg); (F) Diastolic blood pressure (mmHg); (G) Adverse effect; (H) Serious adverse effect.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 17

Metadata

Authors
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C.
Affiliations
  • Third People's Hospital of Chengdu (CN)
  • North Sichuan Medical University (CN)
  • Chongqing Medical University (CN)
Corresponding author
  • Liu, Song
  • Hu, Jiaqiang
Venue
Frontiers in Endocrinology
Published
2025-02-04
Volume
16
Pages
1513641-1513641
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4407146356
Cited by
17
References
31
Citations by year
2026: 8 · 2025: 9
FWCI
2.31
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
incretin-based therapy, GLP-1 receptor agonists, type 2 diabetes, obesity, overweight, weight loss, glycemic control, HbA1c, blood pressure, retatrutide, tirzepatide, mazdutide, semaglutide, dulaglutide, liraglutide
MeSH terms
Network Meta-Analysis as Topic, Glycemic Control, Adult, Blood Glucose, Blood Pressure, Body Weight, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Randomized Controlled Trials as Topic, Treatment Outcome, Overweight, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.3389/fendo.2025.1513641
The paper
Liu, S., Hu, J., Zhao, C., Liu, H., & He, C. (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2025.1513641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.